Abstract
Hepatitis C virus (HCV) infections are a serious viral health problem globally, causing liver cirrhosis and inflammation that can develop to hepatocellular carcinoma and death. Since the HCV NS3/4A protease complex cleaves the scissile peptide bond in the viral encoded polypeptide to release the non-structural proteins during the viral replication process, this protease is then an important target for drug design. The computer-aided drug design and screening targeted at NS3/4A protease of HCV were reviewed. In addition, using steered molecular dynamics simulations, potent inhibitors of the NS3/4A complex were searched for by screening the ZINC database based upon the hypothesis that a high rupture force indicates a high binding efficiency. Nine top-hit compounds (59500093, 59784724, 13527817, 26660256, 29482733, 25977181, 28005928, 13527826 and 13527826) were found that had the same or a greater maximum rupture force (and so assumed binding strength and inhibitory potency) than the four current drugs and so are potential candidates as anti- HCV chemotherapeutic agents. In addition, van der Waals interactions were found to be the main contribution in stabilizing the ligand- NS3/4A complex.
Keywords: NS3/4A protease, hepatitis C virus, steered molecular dynamics simulations.
Current Pharmaceutical Design
Title:In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus
Volume: 20 Issue: 21
Author(s): Arthitaya Meeprasert, Thanyada Rungrotmongkol, Mai Suan Li and Supot Hannongbua
Affiliation:
Keywords: NS3/4A protease, hepatitis C virus, steered molecular dynamics simulations.
Abstract: Hepatitis C virus (HCV) infections are a serious viral health problem globally, causing liver cirrhosis and inflammation that can develop to hepatocellular carcinoma and death. Since the HCV NS3/4A protease complex cleaves the scissile peptide bond in the viral encoded polypeptide to release the non-structural proteins during the viral replication process, this protease is then an important target for drug design. The computer-aided drug design and screening targeted at NS3/4A protease of HCV were reviewed. In addition, using steered molecular dynamics simulations, potent inhibitors of the NS3/4A complex were searched for by screening the ZINC database based upon the hypothesis that a high rupture force indicates a high binding efficiency. Nine top-hit compounds (59500093, 59784724, 13527817, 26660256, 29482733, 25977181, 28005928, 13527826 and 13527826) were found that had the same or a greater maximum rupture force (and so assumed binding strength and inhibitory potency) than the four current drugs and so are potential candidates as anti- HCV chemotherapeutic agents. In addition, van der Waals interactions were found to be the main contribution in stabilizing the ligand- NS3/4A complex.
Export Options
About this article
Cite this article as:
Meeprasert Arthitaya, Rungrotmongkol Thanyada, Li Suan Mai and Hannongbua Supot, In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus, Current Pharmaceutical Design 2014; 20 (21) . https://dx.doi.org/10.2174/13816128113199990632
DOI https://dx.doi.org/10.2174/13816128113199990632 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hashimoto’s Encephalopathy Presenting as Recurrent Brief Psychotic Episodes in a 13-Year-Old Girl: A Case Report
Adolescent Psychiatry Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Pre-Clinical Considerations in the Assessment of Immunogenicity for Protein Therapeutics
Current Drug Safety Host-Pathogen Interactions in Latent Mycobacterium tuberculosis Infection: Identification of New Targets for Tuberculosis Intervention
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Small Molecules Effective Against Liver and Blood Stage Malarial Infection
Current Topics in Medicinal Chemistry Understanding Effects of Psychological Stress on Physiology and Disease Through Human Stressome - An Integral Algorithm
Current Bioinformatics Meet Our Editorial Board Member
Reviews on Recent Clinical Trials Challenges with Mosquito-borne Viral Diseases: Outbreak of the Monsters
Current Topics in Medicinal Chemistry The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells
Current Immunology Reviews (Discontinued) The Use of Lectins as Tools to Combat SARS-CoV-2
Current Pharmaceutical Design Mechanisms of HIV-1 Neurotropism
Current HIV Research Neural Progenitors and HIV-1- Associated Central Nervous System Disease in Adults and Children
Current HIV Research Tau-Focused Immunotherapy for Alzheimers Disease and Related Tauopathies
Current Alzheimer Research Alzheimers Disease: From Pathogenesis to Disease-Modifying Approaches
CNS & Neurological Disorders - Drug Targets Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review
Pharmaceutical Nanotechnology Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research Current Perspectives on Rabies Postexposure Prophylaxis
Infectious Disorders - Drug Targets Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies
Current Medicinal Chemistry